“Unvaccinatable” targets like HIV and hepatitis C were in the bull’s-eye, for the very first time and traditional vaccine technology (live or inactivated viruses), was unable to provide a viable way to provoke a protective immune response against these diseases. However, considerable amount of potential vaccines in the pipeline tends to change the dynamics of the pharmaceutical business in the future.
Serum Institute of India (SII) has opened the world’s largest vaccine manufacturing facility with an investment of USD 0.39 billion in a capacity expansion move aimed at capturing 10-15% share of the international market. SII is the world’s largest vaccine manufacturer by number of doses produced and sold globally with a capacity of 1.5 billion doses. Its 22 vaccines are pre-qualified by WHO.
After the presentation of vaccines against infectious diseases, the world health organization (WHO) reported on the notable decline in mortality and the complications of diseases, which are caused by vaccine`s stability. Records signify the use of vaccines in medical interventions, preventing the death of 5persons per minute and 25 million deaths during the period between 2011 and 2020.
The UNICEF and the WHO have published guidelines on developing a national immunization plan, the comprehensive Multi-Year Plan (cMYP) for all nations across the globe, which intends to ensure equitable access to vaccination facilities for all individuals and increase stakeholder participation in attaining vaccination coverage targets through the designing and implementation of feasible financial strategies to assess current and future program costs that increase the accountability of the respective participants.
How Could Global Next Generation Vaccine Market Addresses The COVID-19 Concerns?
Even the most effective – and draconian – containment strategies have only slowed the spread of the respiratory disease COVID-19. When the World Health Organization finally declares a COVID-19 a pandemic, all eyes have turned to the prospect of a vaccine, because only a vaccine can prevent people from getting sick.
About 35 companies and academic institutions are racing to create such a vaccine, at least four of which already have candidates they have been testing in animals. The first of these – produced by Boston-based biotech firm Moderna – will enter human trials imminently.
Creating a safe vaccine for a new illness is no easy feat. Thankfully, rapid progress is being made for a variety of reasons, including China’s efforts to sequence the genetic material of Sars-CoV-2 and to share that information with research groups around the world. Another factor contributing to the unprecedented speed of development is the fact that coronaviruses were already on the radar of health science researchers. Both SARS and MERS were caused by coronaviruses, and even though vaccines were shelved once those outbreaks were contained, learnings can still be applied to defeating COVID-19.
One of the most promising leads on a COVID-19 vaccine is mRNA-1273. This vaccine, developed by Moderna Therapeutics, is being developed with extreme urgency, skipping straight into human trials before it was even tested in animals. If all goes well with the trials currently underway in Washington State, the company hopes to have an early version of the vaccine ready by fall 2020.
Further down the pipeline are 15 types of subunit vaccines. This method of vaccination uses a fragment of a pathogen, typically a surface protein, to trigger an immune response, teaching the body’s immune system how to fight off the disease without actually introducing live pathogens.
